PharmiWeb.com - Global Pharma News & Resources

General - Press Releases

Date Title Company
02-Nov-2022 Data Reinforcing Impact of Bristol Myers Squibb Cardiovascular Portfolio to be Presented at American Heart Association Scientific Sessions 2022 Businesswire
02-Nov-2022 ROME Therapeutics and Enara Bio to Host Inaugural Dark Genome Symposium Convening Industry and Academic Leaders to Catalyze Therapeutic Application of Dark Genome Research Businesswire
02-Nov-2022 Lusaris Therapeutics Launches with $60 Million Series A Financing to Redefine the Treatment of Severe Neuropsychiatric and Neurological Disorders Businesswire
02-Nov-2022 Global Cannabis Testing Market to Grow at 16.5% Annually Through 2029 - ResearchAndMarkets.com Businesswire
02-Nov-2022 Transdermal Drug Delivery Market Analysis 2022: Technological Advances Present Lucrative Opportunities - ResearchAndMarkets.com Businesswire
02-Nov-2022 CureApp: Digital Therapeutic App for Hypertension Receives Insurance Coverage, Sales of the Service to Medical Institutions Across Japan Launch on September 1 Businesswire
02-Nov-2022 L&T Technology Services Inaugurates Engineering R&D Center in Toronto, Canada Businesswire
02-Nov-2022 First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s) Businesswire
02-Nov-2022 Samenvatting: Noramco kondigt indiening en reactivering aan van het geneesmiddelen master dossier voor actief farmaceutisch ingrediënt methylnaltrexon bromide Businesswire
02-Nov-2022 Arcturus Announces Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines Businesswire
02-Nov-2022 Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Instil Bio, Inc. (TIL) on Behalf of Investors Businesswire
01-Nov-2022 Exelixis and Sairopa Establish Exclusive Clinical Development Collaboration and Option Agreement to Develop ADU-1805, a Potentially Best-in-Class Monoclonal Antibody Targeting SIRPα Businesswire
01-Nov-2022 Exelixis and Cybrexa Therapeutics Establish Exclusive Collaboration Providing Exelixis the Right to Acquire CBX-12, a Potential First-in-Class Peptide-Drug Conjugate of Exatecan Businesswire
01-Nov-2022 Exelixis Announces Third Quarter 2022 Financial Results and Provides Corporate Update Businesswire
01-Nov-2022 Ambrx Biopharma Inc. Appoints Daniel O’Connor as Chief Executive Officer Businesswire
01-Nov-2022 OmniAb Announces Completion of Spin-Off and Business Combination Businesswire
01-Nov-2022 Ligand Announces Completion of OmniAb Spin-Off Businesswire
01-Nov-2022 Anebulo Pharmaceuticals Announces Appointment of Nat Calloway, Ph.D., to Board of Directors Businesswire
01-Nov-2022 Riassunto: Noramco annuncia l'inoltro e la riattivazione del Drug Master File per il principio attivo farmaceutico bromuro di metilnaltrexone Businesswire
01-Nov-2022 Momentive Technologies Completes Acquisition of CoorsTek’s Crucibles Business Businesswire